{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T19:23:40Z","timestamp":1780773820327,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T00:00:00Z","timestamp":1529452800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Satoshi Okamoto Memorial Foundation of Pulmonary Fibrosis"},{"name":"JSPS KAKENHI","award":["26461200"],"award-info":[{"award-number":["26461200"]}]},{"DOI":"10.13039\/100008728","name":"Japan Research Foundation for Clinical Pharmacology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008728","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005865","name":"Mochida Memorial Foundation for Medical and Pharmaceutical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005865","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Yokoyama Foundation for Clinical Pharmacology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s00408-018-0134-6","type":"journal-article","created":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T06:35:42Z","timestamp":1529476542000},"page":"531-541","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Dasatinib Suppresses TGF\u03b2-Mediated Epithelial\u2013Mesenchymal Transition in Alveolar Epithelial Cells and Inhibits Pulmonary Fibrosis"],"prefix":"10.1007","volume":"196","author":[{"given":"Ryota","family":"Kanemaru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8766-5002","authenticated-orcid":false,"given":"Fumiyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoyasu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichiro","family":"Mitsuishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Tajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Ihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moulid","family":"Hidayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Wirawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshika","family":"Koinuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigehiro","family":"Yagishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzo","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fariz","family":"Nurwidya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichiro","family":"Niwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,20]]},"reference":[{"key":"134_CR1","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1164\/rccm.200204-373OC","volume":"167","author":"KR Flaherty","year":"2003","unstructured":"Flaherty KR, Colby TV, Travis WD, Toews GB, Mumford J, Murray S et al (2003) Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med 167:1410\u20131415","journal-title":"Am J Respir Crit Care Med"},{"key":"134_CR2","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/jcp.22448","volume":"226","author":"I Kolosova","year":"2011","unstructured":"Kolosova I, Nethery D, Kern JA (2011) Role of Smad2\/3 and p38 MAP kinase in TGF-beta1-induced epithelial-mesenchymal transition of pulmonary epithelial cells. J Cell Physiol 226:1248\u20131254","journal-title":"J Cell Physiol"},{"key":"134_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1465-9921-6-56","volume":"6","author":"H Kasai","year":"2005","unstructured":"Kasai H, Allen JT, Mason RM, Kamimura T, Zhang Z (2005) TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res 6:56","journal-title":"Respir Res"},{"key":"134_CR4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1146\/annurev-physiol-012110-142225","volume":"73","author":"HA Chapman","year":"2011","unstructured":"Chapman HA (2011) Epithelial-mesenchymal interactions in pulmonary fibrosis. Annu Rev Physiol 73:413\u2013435","journal-title":"Annu Rev Physiol"},{"key":"134_CR5","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr","year":"2014","unstructured":"King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK et al (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370:2083\u20132092","journal-title":"N Engl J Med"},{"key":"134_CR6","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U et al. (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370:2071\u20132082","journal-title":"N Engl J Med"},{"key":"134_CR7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1165\/rcmb.2013-0099OC","volume":"50","author":"Y Xi","year":"2014","unstructured":"Xi Y, Tan K, Brumwell AN, Chen SC, Kim YH, Kim TJ et al (2014) Inhibition of epithelial-to-mesenchymal transition and pulmonary fibrosis by methacycline. Am J Respir Cell Mol Biol 50:51\u201360","journal-title":"Am J Respir Cell Mol Biol"},{"key":"134_CR8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"NP Shah","year":"2004","unstructured":"Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399\u2013401","journal-title":"Science"},{"key":"134_CR9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nrc2126","volume":"7","author":"E Weisberg","year":"2007","unstructured":"Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD (2007) Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 7:345\u2013356","journal-title":"Nat Rev Cancer"},{"key":"134_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.cancergen.2014.02.006","volume":"207","author":"KE Rabenau","year":"2014","unstructured":"Rabenau KE, Dolan M, Yohe S, Ustun C (2014) Effectiveness of dasatinib in accelerated-phase chronic myeloid leukemia with p190 BCR-ABL1 and a second Philadelphia chromosome. Cancer Genet 207:109\u2013110","journal-title":"Cancer Genet"},{"key":"134_CR11","doi-asserted-by":"publisher","first-page":"6905","DOI":"10.1158\/1078-0432.CCR-11-0288","volume":"17","author":"RS Finn","year":"2011","unstructured":"Finn RS, Bengala C, Ibrahim N, Roche H, Sparano J, Strauss LC et al (2011) Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res 17:6905\u20136913","journal-title":"Clin Cancer Res"},{"key":"134_CR12","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3109\/08977194.2015.1109511","volume":"33","author":"O Yilmaz","year":"2015","unstructured":"Yilmaz O, Oztay F, Kayalar O (2015) Dasatinib attenuated bleomycin-induced pulmonary fibrosis in mice. Growth Factors 33:366\u2013375","journal-title":"Growth Factors"},{"key":"134_CR13","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ejphar.2015.11.008","volume":"769","author":"M Abdalla","year":"2015","unstructured":"Abdalla M, Thompson L, Gurley E, Burke S, Ujjin J, Newsome R et al (2015) Dasatinib inhibits TGFbeta-induced myofibroblast differentiation through Src-SRF Pathway. Eur J Pharmacol 769:134\u2013142","journal-title":"Eur J Pharmacol"},{"key":"134_CR14","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1111\/j.1349-7006.2012.02408.x","volume":"103","author":"K Minakata","year":"2012","unstructured":"Minakata K, Takahashi F, Nara T, Hashimoto M, Tajima K, Murakami A et al (2012) Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors. Cancer Sci 103:1946\u20131954","journal-title":"Cancer Sci"},{"key":"134_CR15","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ejphar.2008.06.046","volume":"590","author":"H Oku","year":"2008","unstructured":"Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A et al (2008) Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 590:400\u2013408","journal-title":"Eur J Pharmacol"},{"key":"134_CR16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1378\/chest.130.1.22","volume":"130","author":"N Enomoto","year":"2006","unstructured":"Enomoto N, Suda T, Kato M, Kaida Y, Nakamura Y, Imokawa S et al (2006) Quantitative analysis of fibroblastic foci in usual interstitial pneumonia. Chest 130:22\u201329","journal-title":"Chest"},{"key":"134_CR17","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1136\/jcp.41.4.467","volume":"41","author":"T Ashcroft","year":"1988","unstructured":"Ashcroft T, Simpson JM, Timbrell V (1988) Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 41:467\u2013470","journal-title":"J Clin Pathol"},{"key":"134_CR18","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1165\/ajrcmb.24.3.4293","volume":"24","author":"F Takahashi","year":"2001","unstructured":"Takahashi F, Takahashi K, Okazaki T, Maeda K, Ienaga H, Maeda M et al (2001) Role of osteopontin in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 24:264\u2013271","journal-title":"Am J Respir Cell Mol Biol"},{"key":"134_CR19","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrd2135","volume":"5","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Jabbour E, Grimley J, Kirkpatrick P (2006) Dasatinib. Nat Rev Drug Discov 5:717\u2013718","journal-title":"Nat Rev Drug Discov"},{"key":"134_CR20","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1158\/1078-0432.CCR-10-2616","volume":"17","author":"JC Montero","year":"2011","unstructured":"Montero JC, Seoane S, Ocana A, Pandiella A (2011) Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res 17:5546\u20135552","journal-title":"Clin Cancer Res"},{"key":"134_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1124\/jpet.114.216044","volume":"351","author":"M Hu","year":"2014","unstructured":"Hu M, Che P, Han X, Cai GQ, Liu G, Antony V et al (2014) Therapeutic targeting of SRC kinase in myofibroblast differentiation and pulmonary fibrosis. J Pharmacol Exp Ther 351:87\u201395","journal-title":"J Pharmacol Exp Ther"},{"key":"134_CR22","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1183\/09031936.00152106","volume":"29","author":"NI Chaudhary","year":"2007","unstructured":"Chaudhary NI, Roth GJ, Hilberg F, Muller-Quernheim J, Prasse A, Zissel G et al (2007) Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J 29:976\u2013985","journal-title":"Eur Respir J"},{"key":"134_CR23","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1084\/jem.20041393","volume":"201","author":"A Abdollahi","year":"2005","unstructured":"Abdollahi A, Li M, Ping G, Plathow C, Domhan S, Kiessling F et al (2005) Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 201:925\u2013935","journal-title":"J Exp Med"},{"key":"134_CR24","doi-asserted-by":"publisher","first-page":"e0147005","DOI":"10.1371\/journal.pone.0147005","volume":"11","author":"FF Cruz","year":"2016","unstructured":"Cruz FF, Horta LF, Maia Lde A, Lopes-Pacheco M, da Silva AB, Morales MM et al (2016) Dasatinib reduces lung inflammation and fibrosis in acute experimental silicosis. PLoS ONE 11:e0147005","journal-title":"PLoS ONE"},{"key":"134_CR25","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.1440-1843.2012.02272.x","volume":"18","author":"T Harada","year":"2013","unstructured":"Harada T, Watanabe K, Nabeshima K, Hamasaki M, Iwasaki H (2013) Prognostic significance of fibroblastic foci in usual interstitial pneumonia and non-specific interstitial pneumonia. Respirology 18:278\u2013283","journal-title":"Respirology"},{"key":"134_CR26","first-page":"58","volume":"5","author":"NJ Lomas","year":"2012","unstructured":"Lomas NJ, Watts KL, Akram KM, Forsyth NR, Spiteri MA (2012) Idiopathic pulmonary fibrosis: immunohistochemical analysis provides fresh insights into lung tissue remodelling with implications for novel prognostic markers. Int J Clin Exp Pathol 5:58\u201371","journal-title":"Int J Clin Exp Pathol"},{"key":"134_CR27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12943-015-0468-0","volume":"14","author":"T Bartscht","year":"2015","unstructured":"Bartscht T, Rosien B, Rades D, Kaufmann R, Biersack H, Lehnert H et al (2015) Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad signalling: implications for in vivo mode of action. Mol Cancer 14:199","journal-title":"Mol Cancer"},{"key":"134_CR28","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.lungcan.2010.11.011","volume":"73","author":"JH Chung","year":"2011","unstructured":"Chung JH, Rho JK, Xu X, Lee JS, Yoon HI, Lee CT et al (2011) Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs. Lung Cancer 73:176\u2013182","journal-title":"Lung Cancer"},{"key":"134_CR29","doi-asserted-by":"publisher","first-page":"7328","DOI":"10.18632\/oncotarget.2397","volume":"5","author":"C Wilson","year":"2014","unstructured":"Wilson C, Nicholes K, Bustos D, Lin E, Song Q, Stephan JP et al (2014) Overcoming EMT-associated resistance to anti-cancer drugs via Src\/FAK pathway inhibition. Oncotarget 5:7328\u20137341","journal-title":"Oncotarget"},{"key":"134_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.lungcan.2016.12.012","volume":"104","author":"Y Sesumi","year":"2017","unstructured":"Sesumi Y, Suda K, Mizuuchi H, Kobayashi Y, Sato K, Chiba M et al (2017) Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells. Lung Cancer 104:85\u201390","journal-title":"Lung Cancer"},{"key":"134_CR31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/08923973.2016.1263860","volume":"39","author":"A Mohammadalipour","year":"2017","unstructured":"Mohammadalipour A, Karimi J, Khodadadi I, Solgi G, Hashemnia M, Sheikh N et al (2017) Dasatinib prevent hepatic fibrosis induced by carbon tetrachloride (CCl4) via anti-inflammatory and antioxidant mechanism. Immunopharmacol Immunotoxicol 39:19\u201327","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"134_CR32","doi-asserted-by":"publisher","first-page":"e0140273","DOI":"10.1371\/journal.pone.0140273","volume":"10","author":"S Balasubramanian","year":"2015","unstructured":"Balasubramanian S, Pleasant DL, Kasiganesan H, Quinones L, Zhang Y, Sundararaj KP et al (2015) Dasatinib attenuates pressure overload induced cardiac fibrosis in a murine transverse aortic constriction model. PLoS ONE 10:e0140273","journal-title":"PLoS ONE"},{"key":"134_CR33","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1164\/rccm.200705-715CR","volume":"176","author":"A Bergeron","year":"2007","unstructured":"Bergeron A, Rea D, Levy V, Picard C, Meignin V, Tamburini J et al (2007) Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med 176:814\u2013818","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00408-018-0134-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-018-0134-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-018-0134-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:26:31Z","timestamp":1661473591000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00408-018-0134-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,20]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["134"],"URL":"https:\/\/doi.org\/10.1007\/s00408-018-0134-6","relation":{},"ISSN":["0341-2040","1432-1750"],"issn-type":[{"value":"0341-2040","type":"print"},{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,20]]},"assertion":[{"value":"23 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no conflicts of interest for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All animal experiments were carried out in accordance with the Fundamental Guidelines for Proper Conduct of Animal Experiment and Related Activities in Academic Research Institutions under the jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology (Notice No. 71, 2006) and approved by the Committee for Animal Experimentation of Juntendo University with the Approval No. 290031.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research Involving Human Participants"}}]}}